For most biopharma sponsors, the CRO contract is the single largest commitment in a trial budget. But the number you sign is rarely the number you pay. Between the initial work order and study closeout, a steady stream of change orders reshapes the budget, and each one lands on the desks of clinical operations and finance teams who are already stretched thin.
Managing CRO costs well comes down to one question: when a change order arrives, can you tell what's legitimate and what isn't, fast enough to matter? This post walks through why that's so difficult, how teams have tried to solve it, and how Condor changes the equation with AI.
How to manage CRO costs in clinical trials
Controlling CRO spend isn't about a single negotiation at contract signing. It's a discipline that runs the full life of the study, and it rests on four habits:
- Anchor every cost to its driver. Every line in a CRO budget is ultimately a function of something operational: patients enrolled, sites activated, visits completed, months of study duration. When you know which driver moves which line item, you can tell whether a proposed increase actually follows from a scope change.
- Keep the original contract close. Unit prices, assumptions, and fee schedules in the original work order are your baseline. A change order should adjust scope, not quietly reprice work you've already agreed on.
- Track what's already been done. Work that has already been performed but not yet recognized is one of the most common sources of surprise costs. If you don't know where the study actually stands, you can't tell whether a change order is billing retroactively.
- Know what the change should cost before the CRO tells you. The strongest negotiating position is having your own independent number in hand. Without it, you're reacting to the CRO's figure instead of evaluating it.
These four habits are simple in principle, but hard in practice.
Why CRO change orders are so hard to manage
Change orders have gone from occasional to nearly universal. Protocol amendments - the main trigger for change orders - now affect about 76% of clinical trials, up from 57% a decade ago. In Phase 3, it's 82%, with an average of 3.3 substantial amendments per trial. The later the phase, the bigger the bill: a Phase 3 change order averages roughly $535,000, which is close to four times the Phase 2 average, and takes about three months to negotiate.
Scale that across a portfolio and the numbers get serious. A biotech running eight active studies can expect 40 to 50 change orders across its CROs and ancillary vendors, representing $10 million or more in unplanned, unbudgeted cost. Meanwhile, change order volume has roughly doubled over the past decade while finance headcount has stayed flat. That gap gets absorbed with overtime, missed forecasts, and long weekends.
Volume is only part of it. The documents themselves are built to be hard to review:
The incentives are misaligned. CROs sometimes lowball initial bids, counting on the change order process to recover margin. Once a trial is underway, switching CROs midstream is so costly that sponsors have little leverage.
The information is asymmetric. A change order can be in development at the CRO for months, then arrive with a request to approve it in a week or two. Line-item explanations are often a sentence or two, and unit price increases can be tangled up with legitimate scope changes.
Retroactive work is buried. It's not always clear which scoped work has already occurred. Even well-run CROs struggle to recognize out-of-scope work consistently, and on milestone contracts you may have no visibility into what's been performed. The result is often a large true-up bill at the end.
There's no system of record. Out-of-scope reporting is inconsistent, unit pricing varies across and within trials, and version control can be chaotic. It's not unusual for a CRO to accept a sponsor's pushback in one version, then revert the change in a later one without anyone catching it.
The internal mechanism of a CRO is highly manual and disaggregated. One group manages unit recognition, another builds change order budgets, and a third handles invoicing, often in systems that don't talk to each other. That's how a sponsor ends up billed for 300 remote monitoring visits when only 150 were budgeted.
How sponsors manage CRO change orders compounds the problem further.
How teams have managed CRO change orders to date
Most sponsors handle change orders with some combination of spreadsheets, trackers, and sheer effort. A finance or clinical ops lead exports the CRO budget grid, which can run to hundreds of line items, and works through it line by line, sometimes literally with a ruler, comparing it against the original contract and whatever out-of-scope tracker exists. Questions go back to the CRO by email, a revised version comes back, and the cycle repeats four or five times.
When sponsors want to know what a scope change might cost in advance, they typically ask the CRO. The process on the CRO side is often less rigorous than it looks. When Jeff was at a CRO, a sponsor asking what it would cost to add 15 patients or expand into new regions would get a modeled estimate with a 20% buffer on top, delivered as a single ballpark number a week or two later. The sponsor gets an answer, but it's the CRO's answer, on the CRO's timeline.
More recently, teams have started using generic AI tools like Microsoft Copilot or ChatGPT for a first pass. That's a genuine improvement. With a well-structured prompt, a generic model can summarize what changed in a change order, identify the largest cost increases, and draft a CFO-ready memo in under a minute, with no procurement required. (We shared the exact prompt in our webinar recap).
But generic AI hits a ceiling quickly. It can tell you what a document says, not whether it's right. It has no knowledge of your original contract, your protocol history, or what "normal" looks like for a study like yours. It won't reliably catch unlabeled retroactive work, and it can return a different answer every time you run the same prompt. It gets you from zero to informed. But it doesn't get you to defensible.
How to manage CRO change orders with Condor’s AI platform
Condor is the AI platform for biopharma R&D. It's built on a proprietary clinical and financial ontology and knowledge graph, co-developed with Big 4 accounting firms, that maps how budgets, vendor contracts, sites, and clinical activity actually connect. That foundation is what lets Condor's AI reason about a change order the way an experienced clinical finance team would.
Condor supports change order management two ways: reviewing change orders once they arrive, and getting ahead of them before they do.
Reviewing a change order: from "what changed" to "what's wrong"
When a change order comes in, Talon, Condor's purpose-built AI analysis service, evaluates every line item against the original contract and the study's cost drivers. Instead of just summarizing changes, it makes judgment calls. Each line is sorted into a clear disposition: hard no, push back, needs clarification, or accept.
In a live demo, we ran a $2.25 million Phase 3 change order through Talon, an internally built AI analysis platform used by our customer success team. It found that roughly 94% of the dollar delta was unjustified, inadequately supported, or needed clarification. It identified $1.4 to $1.7 million in recoverable savings, along with a realistic settlement range of $556,000 to $856,000, since no CRO concedes everything.
The reasoning is what makes it useful. The largest increase in that change order was clinical monitoring, which the CRO had scaled with the number of added sites. Talon flagged that monitoring cost is driven primarily by patient volume and source data verification, not site count. Since patient enrollment wasn't changing, most of that increase didn't hold up. Talon reverse-engineered the expected cost from the original contract's drivers, showed the gap, and linked every finding back to the source cell in the budget grid. It then produced a negotiation brief with talking points the team could send straight back to the CRO.
Getting ahead of the change order: scenario planning
The bigger shift is flipping the sequence entirely. With Condor's clinical finance agent, you can model a scope change yourself, in plain language, before the CRO sends anything.
In the same demo, we asked the agent to forecast a scenario that mirrored the CRO's proposed change: add sites, keep the 48-month duration, and hold patient counts flat. In seconds, the agent loaded the study's forecast, recalculated it against the actual contract structure and cost drivers, and saved it as a new scenario. The result was a $629,000 incremental increase across the full trial, compared to more than $2 million in the CRO's change order for the same scope.
That's the difference between reacting and negotiating. When you know what a reasonable change order looks like before it arrives, the conversation starts from your number, not the CRO's.
Scenario planning works for any what-if your team is weighing. Behind on enrollment? You can compare the cost of adding countries versus adding sites. Unsure what a realistic enrollment rate looks like? Condor can reference comparable trials on ClinicalTrials.gov with similar indications, size, and site mix to back into a reasonable assumption.
The benefits of managing CRO change orders with Condor
You recover real money. One commercial-stage pharma sponsor running 20 studies has saved more than $21 million in unjustified CRO billings in under two years with Condor. Across our customers, teams see up to 30% budget savings, alongside 90%+ forecast accuracy and 70% faster month-end close.
You negotiate from a position of strength. Scenario planning gives you an independent, defensible estimate before the CRO's number arrives. That reverses the information asymmetry that CROs have historically relied on.
Your findings are defensible. Condor's deterministic math layer produces consistent answers every time, with AI reasoning layered on top. Every finding traces back to its source. The platform includes a full audit trail of every change, whether made by a user or an agent, with SOX controls, sign-offs, and user permissions built in. Condor is SOC 1 Type 2 and SOC 2 Type 2 compliant.
You catch what's hidden. Line-item comparisons to the original contract, driver-level analysis, and retrospective flags surface the costs that generic tools miss, including unit price creep, retroactive billing, and increases that don't follow from the actual scope change.
You close the capacity gap. Change order volume has doubled while team sizes haven't. Condor absorbs the line-by-line review work so your team can spend its time on judgment and negotiation rather than untangling budget grids.
It extends beyond CROs. The same approach applies across your vendor portfolio, including labs, patient recruitment vendors, and site CTAs. Condor integrates directly with your ERP, EDC, contract, and procurement systems, so there's no need for special templates or manual data transformation.
Stop reacting to change orders
Protocol amendments aren't going away, and neither are change orders. What can change is how prepared your team is when one arrives. Generic AI can tell you what a change order says. Condor tells you what it's hiding, and helps you know what it should cost before it ever reaches your desk.
Want to see what this looks like with your own studies? Book a demo with our team.
